KIM CONLIN: Open Payments
NPI 1497065072 · BOZEMAN, MT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$632 in 24 payments from 11 companies in 2025. Trend: 2023 $690 · 2024 $753 · 2025 $632
Food & beverage: $632
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 5 | $115 |
| Penumbra, Inc. | 1 | $90 |
| Merck Sharp & Dohme LLC | 4 | $89 |
| AstraZeneca Pharmaceuticals LP | 4 | $85 |
| Stemline Therapeutics Inc. | 3 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $72 |
| ADC THERAPEUTICS AMERICA, INC. | 1 | $24 |
| TerSera Therapeutics LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Aadi Bioscience, Inc. | 1 | $18 |
Products named: Indigo System, Orserdu, LIBTAYO, DARZALEX, KEYTRUDA, RYBREVANT, ZYNLONTA, Xermelo.
Industry payments across MT — which companies pay providers there.
